The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare autoimmune disorder about 75,000 to 100,000 people in the US have this disease.

This disease is more common to females between the ages of 30 and 50. As per the United Nations, the global population in 2019 was 7.7 billion, out of which, around 4 billion are females. Out of this, around 50% is the target population in the age range of 15 to 50 years. It is equivalent to around 1.9 billion of the female population. This population is expected to increase to around 2.1 billion by 2025. The rapid increase in the number of the disease-prone population is anticipated to be a key factor contributing to the growth of the scleroderma therapeutics market across the globe.

Get Sample Copy of Scleroderma Therapeutics Market at: https://www.omrglobal.com/request-sample/scleroderma-therapeutics-market

Top Key Players - Boehringer Ingelheim International GmbH, Celgene Corp., arGentis Pharmaceuticals, LLC, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, Inc., Cytori Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Bayer AG, F. Hoffmann La-Roche Ltd.,

Bristol-Myers Squibb Company, and so on are the prominent players operating in the scleroderma therapeutics market across the globe. The major players of the market are making hefty investments in the R&D of novel therapies for the improved treatment of scleroderma. The continuous efforts of the market players in the development of new therapies are driving the growth of the global market.

The recent development in Market

In June 2020, Bristol Laboratories Ltd., a UK-based pharmaceutical company had launched Amlodipine besilate tablets in 2.5mg dose. Amlodipine belongs to the class of calcium channel blockers. The launch of this medicine is anticipated to make a contribution to the market growth of scleroderma therapeutics.

For More Information, get A full report of Scleroderma Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/scleroderma-therapeutics-market

In September 2019, Correvio Pharma Corp. pharmaceutical company focused on commercializing hospital drugs had received US FDA approval to review United Therapeutics Corporation's New Drug Application (NDA) for Trevyent (treprostinil) for the treatment of pulmonary arterial hypertension (PAH).

Global Scleroderma Therapeutics Market Segmentation

By Drug Type

Phosphodiesterase 5 inhibitors – PHA
Prostacyclin Analogues
Immunosuppressors
Endothelin Receptor Antagonists
Calcium Channel Blockers
Others
Bu Disease Type

Systemic Scleroderma
Localized Scleroderma
Global Scleroderma Therapeutics Market – Segment by Region

North America

United States
Canada
Europe

UK
Germany
Italy
Spain
France
Rest of Europe
Asia-Pacific

China
Japan
India
Rest of the Asia-Pacific


For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/scleroderma-therapeutics-market



About Orion Market Research



Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/


Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 7803040404